A 12-week, randomized, double-blind, controlled study in 1670 patients with moderate-to-severe acne vulgaris demonstrated significantly greater lesion reduction with adapalene 0. The fixed combination reduced inflammatory and non-inflammatory lesions by approximately 60% at week 12 with acceptable tolerability.
First-line for moderate-to-severe acne when topical-only therapy is appropriate. Apply once nightly. Use a gentle cleanser and ceramide moisturizer to manage barrier disruption in weeks 1–4.
If you're targeting acne, this research supports adding adapalene to your PM routine. Effective concentration range: 60% based on this study. Timeline to expect: 12 weeks based on study duration.
If you're targeting acne, this research supports adding benzoyl peroxide to your AM/PM routine. Effective concentration range: 60% based on this study. Timeline to expect: 12 weeks based on study duration.
Translated from this study's findings, not a personal prescription. Pair with your existing protocol and your practitioner's guidance.
A 12-week RCT in 1670 patients found adapalene 0.1%–BPO 2.5% fixed combination produced ~60% reduction in both inflammatory and non-inflammatory lesions, statistically superior to either monotherapy. Combination addresses two distinct pathways: retinoid normalizes follicular keratinization, BPO targets P. acnes biofilm.
A 12-week, randomized, double-blind, controlled study in 1670 patients with moderate-to-severe acne vulgaris demonstrated significantly greater lesion reduction with adapalene 0.1%-BPO 2.5% versus monotherapy with either agent. The fixed combination reduced inflammatory and non-inflammatory lesions by approximately 60% at week 12 with acceptable tolerability.
Original source →Friedreich's ataxia is a rare, chronic, progressive, neurodegenerative condition affecting multiple organ systems, including neurological, musculoskeletal, cardiac, and endocrine systems, and is marked by low cardiopulmonary fitness. We tested the effect of exercise and NAD+ precursor supplementation with nicotinamide riboside, which have each shown benefits in animal and early clinical studies, on cardiopulmonary fitness in individuals with Friedreich's ataxia. This 12-week, outpatient, phase 2, single-site (Children's Hospital of Philadelphia, Philadelphia, PA, USA), randomised, 2 × 2 factorial clinical trial recruited individuals aged 10-40 years with an ejection fraction of 45% or greater who were able to exercise.
Recent preclinical studies have shown that nicotinamide adenine dinucleotide (NAD+) plays a critical role in molecular mechanisms of axon degeneration, and reductions in NAD+ levels are associated with axonal degeneration. Nicotinamide riboside (NR) is a safe and widely available pyridine-nucleoside form of vitamin B3 and is an NAD+ precursor. To investigate if oral supplementation of synthetic NR can act as a therapeutic agent to prevent degeneration of small somatic sensory axons innervating the skin or promote regeneration of these same fibers in humans, we utilized a validated experimental model of cutaneous nerve degeneration and regeneration and conducted a placebo-controlled, double-blinded Phase 2 study.
Nicotinamide (NAM) and Polypodium leucotomos extract (PL) have demonstrated photoprotective effects, but their role in preventing UVA-induced DNA damage in humans remains unclear. To evaluate the effects of oral NAM and PL on UVA-induced erythema and thymidine dimer (TT-dimer) formation. In this intraindividual trial, 50 healthy volunteers (phototypes I-III) were randomized (1:1) to receive either NAM (2000 mg daily) or PL (Heliocare Advanced: 480 mg daily) for 30 days.
This information is for educational purposes only and is not medical advice. Individual results vary. Consult a qualified dermatologist or healthcare professional for medical concerns. Full disclaimer →